Minirin Melt 60 μg, 120 μg, 240 μg Sublingual tablet
PDF Leaflet Revision Date: 9 February 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Management of central diabetes insipidus and primary nocturnal enuresis in children over 5 years.
Dosage (summary)
Central diabetes insipidus: 60 u03bcg three times daily; Primary nocturnal enuresis: 120 u03bcg at bedtime, may increase to 240 u03bcg.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy not established; unknown if excreted in breast milk.
Key Drug Interactions
- Tricyclic antidepressants
- SSRIs
- Carbamazepine
- NSAIDs
Contraindications
- Hypersensitivity to desmopressin
- Nephrogenic diabetes insipidus
- Moderate/severe renal insufficiency
- Known hyponatraemia
Common side effects
- Hyponatraemia
- Headache
- Dizziness
- Nausea
- Vomiting
Counselling Points
- Adhere to fluid restrictions
- Monitor for signs of hyponatraemia
- May cause somnolence and dizziness
Serious warnings
- Risk of water intoxication and hyponatraemia
- Fluid intake must be limited during treatment
Important Disclaimer
The Minirin Melt 60 μg, 120 μg, 240 μg Sublingual tablet professional information leaflet below is the property of Ferring and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
